Chicory root

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: digestion weight heart

Research Overview

Across the provided abstracts, chicory root research has most heavily focused on its role as a fermentable dietary fiber source—particularly chicory-derived inulin/inulin-type fructans (ITF)—and consequent effects on the gut microbiome and short-chain fatty acid (SCFA) production. Human intervention work includes randomized, placebo-controlled crossover trials using ITF-enriched snack bars (3–7 g/day for 4 weeks) with 16S rRNA profiling, as well as shorter supplementation studies comparing inulin to other fermentable substrates. Complementary in vitro fecal fermentation studies compare chicory-derived fibers (pure inulin and whole chicory-root preparations containing inulin plus other polysaccharides) to other fibers for gas and SCFA outputs. Beyond fiber, mechanistic and compositional studies in animal models and extracts examine additional chicory-root constituents (e.g., chlorogenic acids, chicoric acid, sesquiterpene lactones, fructose) for metabolic, inflammatory, antimicrobial, and appetite-related effects, including antidiabetic activity in rodent models.

The strongest evidence in these abstracts supports a prebiotic effect of chicory root inulin/ITF in humans, most consistently reflected as increased relative abundance of Bifidobacterium with low-to-moderate doses incorporated into foods, and generally good tolerability at the tested doses. Evidence for downstream functional outputs is more mixed: while SCFA production is a central rationale, the controlled human snack-bar trials reported time effects but not clear treatment effects on fecal SCFA concentrations, and comparative supplementation work suggests chicory inulin may not be the most potent substrate for increasing butyrate relative to certain resistant starches. In vitro fermentation studies indicate chicory-derived fibers are fermentable and can shift SCFA profiles, but results vary by substrate type (pure inulin vs whole-root matrices), time course, and donor microbiota, limiting direct translation to clinical endpoints.

Key gaps include (1) more human trials linking chicory root interventions to clinically meaningful outcomes (e.g., glycemic control, lipids, inflammatory markers, IBS-related symptoms) rather than microbiome composition alone; (2) better characterization of dose–response, inter-individual variability, and durability of effects, including identification of microbiome features predicting response; and (3) mechanistic disentangling of which chicory-root components drive which effects, since animal nutrigenomic work implicates multiple compound classes and extract studies suggest whole-extract activity may differ from isolated major constituents. Additional needs include standardized reporting of fiber chemistry (degree of polymerization, matrix effects), harmonized SCFA measurement approaches (fecal vs circulating), and longer-term safety/tolerability data across broader populations (e.g., metabolic disease, older adults).

1. What conditions has Chicory root been studied for?

  • Gut microbiome modulation / prebiotic effects (especially via chicory root inulin/inulin-type fructans): studied in healthy adults and in vitro fermentation models.

  • Short-chain fatty acid (SCFA) production (e.g., butyrate, propionate): studied in healthy adults (dietary supplementation) and in vitro fecal fermentation systems.

  • Dietary fiber gap / increasing fiber intake: chicory inulin-type fructans added to snack bars in adults with low habitual fiber intake.

  • Gastrointestinal (GI) disorders (traditional use context): a review of EMA-listed medicinal plants notes chicory root/inulin as among the more robustly studied prebiotics, though many herbal GI drugs lack microbiome-focused studies.

  • Glycemic control / diabetes-related outcomes: animal studies of chicory root extracts rich in chicoric acid and chlorogenic acid in streptozotocin (STZ) diabetic rats; murine work examining chicory root constituents (fructose, chlorogenic acids, sesquiterpene lactones) with metabolic and appetite-related endpoints.

  • Lipid metabolism, inflammation, appetite regulation: murine nutrigenomic/hormonal/microbiota work suggests hypolipidemic, anti-inflammatory, and appetite-regulatory signals (mechanistic/animal evidence).

  • Animal production/toxicology-adjacent endpoints: pig studies including chicory root feeding affecting hepatic cytochrome P450 activity (CYP1A2/2A/2E1) and studies on pig intestinal microenvironment.

2. Does it work in treating those conditions? Summarize the evidence.

  • Prebiotic/microbiome effects in humans: supported. In two 4-week, placebo-controlled, double-blind, crossover trials in healthy adults with low fiber intake, snack bars providing 7 g/day chicory root inulin-type fructans increased Bifidobacterium (mean ± SEM from 5.3% ± 5.9% to 18.7% ± 15.0%). With 3 g/day, the increase was less robust by 16S after multiple-comparison correction, but qPCR still showed a significant increase.

  • SCFA increases in humans: mixed/limited. In the 4-week snack bar trials, fecal SCFAs changed over time but not by treatment, despite microbiome shifts. In a separate 2-week study in 174 healthy young adults comparing fibers, inulin from chicory root was one of the interventions, but resistant potato starch produced the greatest increase in total SCFAs (including butyrate), implying chicory inulin was not the top performer in that trial.

  • GI symptom improvement in healthy adults: not demonstrated in the cited trial. In the snack bar trials, there were no between-group differences in GI symptoms versus control.

  • Glycemic control/antidiabetic effects: promising but primarily animal data. In STZ diabetic rats, a chicory root extract rich in chicoric acid (64.2%) and chlorogenic acid (noted among caffeoylquinic acids) improved glucose tolerance after 7 days; the whole extract also significantly decreased basal hyperglycemia after 6 days, whereas a synthetic mixture of the two major compounds improved glucose tolerance but appeared less effective on basal hyperglycemia. These are not human clinical outcomes.

  • Other proposed benefits (anti-inflammatory, hypolipidemic, appetite regulation): not confirmed clinically in these abstracts. A murine nutrigenomic/hormonal/microbiota study reports multiple mechanistic signals and attributes a large share of recorded responses to fructose, but this remains preclinical and does not establish treatment efficacy in humans.

Overall: the strongest direct evidence in these abstracts is for prebiotic microbiome modulation (notably Bifidobacterium increases) in healthy adults. Evidence for treating specific diseases (e.g., diabetes) is largely animal-based here, and evidence for increasing fecal SCFAs in humans is inconsistent across studies.

3. What health benefits does it have?

  • Prebiotic effect (most consistent human evidence): Chicory root inulin-type fructans increased Bifidobacterium in healthy adults at both 7 g/day (clear by 16S) and 3 g/day (supported by targeted qPCR).

  • Helps increase fiber intake: In the snack bar trials, adding 3 g/day or 7 g/day inulin-type fructans significantly increased total fiber intake, addressing the “fiber gap.”

  • Potential SCFA-related benefits (mechanistic plausibility; variable human signal): Inulin is a fermentable fiber and is studied for SCFA production; however, in the cited 4-week human trial, fecal SCFAs were not significantly different by treatment, and in the 2-week comparison trial other fibers (potato resistant starch) increased SCFAs more.

  • Metabolic benefits suggested in animals: Chicory root extracts (chicoric/chlorogenic-acid rich) improved glucose tolerance in diabetic rats, and murine work suggests anti-inflammatory, hypolipidemic, hypoglycemic, antioxidant, antimicrobial, and appetite-regulatory signals. These findings are hypothesis-generating for humans.

4. Does it have any downsides or side effects?

  • GI tolerability in the cited human trial was good at 3–7 g/day: In the 4-week placebo-controlled crossover trials, there were no between-group differences in GI symptoms with chicory inulin-type fructans snack bars versus control.

  • Potential for fermentation-related symptoms (not quantified in these abstracts): As a fermentable fiber, inulin-type fructans commonly increase colonic fermentation; while not observed as worse symptoms in the cited trial, some individuals may experience gas/bloating at higher doses in general (this is a general limitation: the provided abstracts do not detail adverse event rates beyond “no between-group differences”).

  • Uncertain relevance of animal CYP findings to human safety: A pig study found chicory feeding altered gonadal steroid–dependent inhibition of certain hepatic CYP activities. This does not directly demonstrate harm in humans, but it suggests chicory-containing diets could, in some contexts, influence xenobiotic metabolism pathways (evidence is indirect and species-specific).

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

  • No direct human pharmacogenomic evidence is provided in these abstracts. None of the cited human chicory/inulin trials stratified outcomes by genotype or reported gene–supplement interactions.

  • Indirect mechanistic relevance (not pharmacogenomics, but metabolism-related): In pigs, chicory root feeding was associated with changes in hepatic cytochrome P450 activity patterns (CYP1A2/2A/2E1 context). While CYP enzymes are relevant to pharmacogenomics in humans, these data are animal-based and do not establish that specific human CYP genotypes would experience benefit or harm from chicory root.

Bottom line: based on the provided abstracts, chicory root (primarily via inulin-type fructans) has the best evidence for beneficial microbiome modulation in healthy adults, with no clear GI symptom worsening at 3–7 g/day in one controlled trial. Claims for disease treatment (e.g., diabetes) are not yet supported by human clinical evidence in these abstracts, and pharmacogenomic implications remain undetermined.

References

  1. Dynamics of Human Gut Microbiota and Short-Chain Fatty Acids in Response to Dietary Interventions with Three Fermentable Fibers.
    Nielson T Baxter, Alexander W Schmidt, Arvind Venkataraman, Kwi S Kim, Clive Waldron, Thomas M Schmidt (2019) - mBio
  2. Prebiotic Dietary Fiber and Gut Health: Comparing the in Vitro Fermentations of Beta-Glucan, Inulin and Xylooligosaccharide.
    Justin L Carlson, Jennifer M Erickson, Julie M Hess, Trevor J Gould, Joanne L Slavin (2017) - Nutrients
  3. The role of gut microbiota for the activity of medicinal plants traditionally used in the European Union for gastrointestinal disorders.
    Timo A Thumann, Eva-Maria Pferschy-Wenzig, Christine Moissl-Eichinger, Rudolf Bauer (2019) - Journal of ethnopharmacology
  4. Effect of chicory inulin-type fructan-containing snack bars on the human gut microbiota in low dietary fiber consumers in a randomized crossover trial.
    Raylene A Reimer, Adriana Soto-Vaca, Alissa C Nicolucci, Shyamchand Mayengbam, Heekuk Park, Karen L Madsen, Ravi Menon, Elaine E Vaughan (2020) - The American journal of clinical nutrition
  5. Chicory: Understanding the Effects and Effectors of This Functional Food.
    Céline L Pouille, Souad Ouaza, Elise Roels, Josette Behra, Melissa Tourret, Roland Molinié, Jean-Xavier Fontaine, David Mathiron, David Gagneul, Bernard Taminiau, Georges Daube, Rozenn Ravallec, Caroline Rambaud, Jean-Louis Hilbert, Benoit Cudennec, Anca Lucau-Danila (2022) - Nutrients
  6. Increase in insulin sensitivity by the association of chicoric acid and chlorogenic acid contained in a natural chicoric acid extract (NCRAE) of chicory (Cichorium intybus L.) for an antidiabetic effect.
    Karine Ferrare, Luc P R Bidel, Abdulmomem Awwad, Patrick Poucheret, Guillaume Cazals, Françoise Lazennec, Jacqueline Azay-Milhau, Michel Tournier, Anne-Dominique Lajoix, Didier Tousch (2018) - Journal of ethnopharmacology
  7. Determination of prebiotic activity and probiotic encapsulation ability of inulin type fructans obtained from Inula helenium roots.
    Hilal Dikmen Meral, Fahriye Şeyma Özcan, Nihat Özcan, Fatih Bozkurt, Osman Sağdiç (2024) - Journal of food science
  8. Gender-related differences in cytochrome P450 in porcine liver--implication for activity, expression and inhibition by testicular steroids.
    M K Rasmussen, G Zamaratskaia, B Ekstrand (2011) - Reproduction in domestic animals = Zuchthygiene
  9. Inclusion of chicory (Cichorium intybus L.) in pigs' diets affects the intestinal microenvironment and the gut microbiota.
    Haoyu Liu, Emma Ivarsson, Johan Dicksved, Torbjörn Lundh, Jan Erik Lindberg (2012) - Applied and environmental microbiology
  10. The effects of fermentation products of prebiotic fibres on gut barrier and immune functions in vitro.
    Van T Pham, Nicole Seifert, Nathalie Richard, Daniel Raederstorff, Robert E Steinert, Kevin Prudence, M Hasan Mohajeri (2018) - PeerJ
  11. Significance of Inulin Fructans in the Human Diet.
    Gertjan Schaafsma, Joanne L Slavin (2015) - Comprehensive reviews in food science and food safety
  12. Functional yogurt aims to protect against the aflatoxin B1 toxicity in rats.
    Ahmed M Abdel-Salam, Ahmed Noah Badr, Ahmed H Zaghloul, Abdel Razik H Farrag (2020) - Toxicology reports
  13. Plants of the Spontaneous Flora with Beneficial Action in the Management of Diabetes, Hepatic Disorders, and Cardiovascular Disease.
    Maria Valentina Ignat, Teodora Emilia Coldea, Liana Claudia Salanță, Elena Mudura (2021) - Plants (Basel, Switzerland)
  14. Effect of the dietary polyphenolic fraction of chicory root, peel, seed and leaf extracts on caecal fermentation and blood parameters in rats fed diets containing prebiotic fructans.
    Jerzy Juśkiewicz, Zenon Zduńczyk, Ewa Zary-Sikorska, Bogusław Król, Joanna Milala, Adam Jurgoński (2011) - The British journal of nutrition
  15. Back to the Roots: Revisiting the Use of the Fiber-Rich Cichorium intybusL. Taproots.
    Marie-Luise Puhlmann, Willem M de Vos (2020) - Advances in nutrition (Bethesda, Md.)
  16. Inulin: a multifaceted ingredient in pharmaceutical sciences.
    Ruchi Tiwari, Pranshul Sethi, Shashi Ravi Suman Rudrangi, Pavan Kumar Padarthi, Vinod Kumar, Samatha Rudrangi, Krishna Vaghela (2024) - Journal of biomaterials science. Polymer edition
  17. Novel Biodegradable Starch Film for Food Packaging with Antimicrobial Chicory Root Extract and Phytic Acid as a Cross-Linking Agent.
    Andrzej Jaśkiewicz, Grażyna Budryn, Agnieszka Nowak, Magdalena Efenberger-Szmechtyk (2020) - Foods (Basel, Switzerland)
  18. The Influence of Topinambur and Inulin Preventive Supplementation on Microbiota, Anxious Behavior, Cognitive Functions and Neurogenesis in Mice Exposed to the Chronic Unpredictable Mild Stress.
    Joanna Szala-Rycaj, Aleksandra Szewczyk, Mirosław Zagaja, Agnieszka Kaczmarczyk-Ziemba, Maciej Maj, Marta Andres-Mach (2023) - Nutrients
  19. The effects of inulin, dried Jerusalem artichoke tuber and a multispecies probiotic preparation on microbiota ecology and immune status of the large intestine in young pigs.
    Marcin Barszcz, Marcin Taciak, Jacek Skomiał (2016) - Archives of animal nutrition
  20. In vivo effect of dried chicory root (Cichorium intybus L.) on xenobiotica metabolising cytochrome P450 enzymes in porcine liver.
    Martin Krøyer Rasmussen, Galia Zamaratskaia, Bo Ekstrand (2011) - Toxicology letters


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!